Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290516 | 0.89 | RNASE1 (0.43) | RNASE1 | |
| SCHEMBL2594578 | 0.89 | RNASE1 (0.42) | RNASE1 | |
| SCHEMBL6830784 | 0.84 | RNASE1 (0.39) | RNASE1 | |
| SCHEMBL9693407 | 0.83 | RNASE1 (0.40) | RNASE1DUT | |
| SCHEMBL2710677 | 0.82 | RNASE1 (0.39) | RNASE1DUT | |
| SCHEMBL9342955 | 0.81 | RNASE1 (0.42) | RNASE1DUT | |
| SCHEMBL8027668 | 0.80 | RNASE1 (0.41) | RNASE1 | |
| SCHEMBL5477613 | 0.80 | RNASE1 (0.42) | RNASE1 | |
| SCHEMBL9342953 | 0.79 | RNASE1 (0.44) | RNASE1DUT | |
| SCHEMBL2561711 | 0.79 | DUT (0.62) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447274-B1 | Oligomeric compounds and methods | IONIS PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9738895-B2 | Oligomeric compounds and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150167006-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8987435-B2 | Oligomeric compounds and methods | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| EP-2447274-A2 | Oligomeric compounds and methods | Isis Pharmaceuticals, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | RNASE1 1050/4885DUT 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.